Skip to main content

The pharmacogenetics of antiplatelet agents: towards personalized therapy?

Publication ,  Journal Article
Ahmad, T; Voora, D; Becker, RC
Published in: Nat Rev Cardiol
August 9, 2011

Considerable variability exists in how individual patients respond to oral antiplatelet therapy, specifically to aspirin and to P2Y(12)-receptor inhibitors such as clopidogrel. This variability translates to differences in clinical outcomes and might in part be as a result of common variation within genes that are involved in the absorption, metabolic activation, and biological activity of these medications. The field of pharmacogenetics has yielded several genetic loci that predict variation in patient response to antiplatelet therapies. The most robust data indicate an association between loss-of-function alleles of the CYP2C19 gene and adverse outcomes among high-risk patients treated with clopidogrel. However, several fundamental questions surrounding the information gained from genotyping and the efficacy of modifying therapy on the basis of testing remain unanswered. Routine genetic testing for platelet responsiveness cannot, therefore, be recommended for clinical decision-making. Ongoing and future clinical trials might provide evidence to support a change in practice towards pharmacogenetic-based selection of antiplatelet therapy.

Duke Scholars

Published In

Nat Rev Cardiol

DOI

EISSN

1759-5010

Publication Date

August 9, 2011

Volume

8

Issue

10

Start / End Page

560 / 571

Location

England

Related Subject Headings

  • Precision Medicine
  • Platelet Aggregation Inhibitors
  • Phenotype
  • Pharmacogenetics
  • Patient Selection
  • Humans
  • Genotype
  • Genetic Testing
  • Drug Resistance
  • Cardiovascular System & Hematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ahmad, T., Voora, D., & Becker, R. C. (2011). The pharmacogenetics of antiplatelet agents: towards personalized therapy? Nat Rev Cardiol, 8(10), 560–571. https://doi.org/10.1038/nrcardio.2011.111
Ahmad, Tariq, Deepak Voora, and Richard C. Becker. “The pharmacogenetics of antiplatelet agents: towards personalized therapy?Nat Rev Cardiol 8, no. 10 (August 9, 2011): 560–71. https://doi.org/10.1038/nrcardio.2011.111.
Ahmad T, Voora D, Becker RC. The pharmacogenetics of antiplatelet agents: towards personalized therapy? Nat Rev Cardiol. 2011 Aug 9;8(10):560–71.
Ahmad, Tariq, et al. “The pharmacogenetics of antiplatelet agents: towards personalized therapy?Nat Rev Cardiol, vol. 8, no. 10, Aug. 2011, pp. 560–71. Pubmed, doi:10.1038/nrcardio.2011.111.
Ahmad T, Voora D, Becker RC. The pharmacogenetics of antiplatelet agents: towards personalized therapy? Nat Rev Cardiol. 2011 Aug 9;8(10):560–571.

Published In

Nat Rev Cardiol

DOI

EISSN

1759-5010

Publication Date

August 9, 2011

Volume

8

Issue

10

Start / End Page

560 / 571

Location

England

Related Subject Headings

  • Precision Medicine
  • Platelet Aggregation Inhibitors
  • Phenotype
  • Pharmacogenetics
  • Patient Selection
  • Humans
  • Genotype
  • Genetic Testing
  • Drug Resistance
  • Cardiovascular System & Hematology